IL300387A - 6-mutated pyridazine compounds as SMARCA2 and/or SMARCA4 derivatives - Google Patents

6-mutated pyridazine compounds as SMARCA2 and/or SMARCA4 derivatives

Info

Publication number
IL300387A
IL300387A IL300387A IL30038723A IL300387A IL 300387 A IL300387 A IL 300387A IL 300387 A IL300387 A IL 300387A IL 30038723 A IL30038723 A IL 30038723A IL 300387 A IL300387 A IL 300387A
Authority
IL
Israel
Prior art keywords
phenyl
cancer
hydroxy
alkyl
compound
Prior art date
Application number
IL300387A
Other languages
English (en)
Hebrew (he)
Original Assignee
Aurigene Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Oncology Ltd filed Critical Aurigene Oncology Ltd
Publication of IL300387A publication Critical patent/IL300387A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL300387A 2020-08-04 2021-08-03 6-mutated pyridazine compounds as SMARCA2 and/or SMARCA4 derivatives IL300387A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041033326 2020-08-04
PCT/IB2021/057089 WO2022029617A1 (en) 2020-08-04 2021-08-03 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders

Publications (1)

Publication Number Publication Date
IL300387A true IL300387A (en) 2023-04-01

Family

ID=80117730

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300387A IL300387A (en) 2020-08-04 2021-08-03 6-mutated pyridazine compounds as SMARCA2 and/or SMARCA4 derivatives

Country Status (11)

Country Link
US (2) US12570650B2 (cg-RX-API-DMAC7.html)
EP (1) EP4192835A4 (cg-RX-API-DMAC7.html)
JP (2) JP7857914B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230061349A (cg-RX-API-DMAC7.html)
CN (1) CN116529250A (cg-RX-API-DMAC7.html)
AU (1) AU2021320052A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002089A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188024A1 (cg-RX-API-DMAC7.html)
IL (1) IL300387A (cg-RX-API-DMAC7.html)
MX (1) MX2023001445A (cg-RX-API-DMAC7.html)
WO (1) WO2022029617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
AU2024348074A1 (en) 2023-09-27 2026-04-30 Haisco Pharmaceutical Group Co., Ltd. Pyrazole carboxylic acid derivative and use thereof in medicine
WO2025196686A1 (en) * 2024-03-20 2025-09-25 Aurigene Oncology Limited Fused bicyclic compounds as smarca2 and/or smarca4 degraders
CN119874808B (zh) * 2025-01-02 2026-04-17 四川大学 一种靶向smarca蛋白降解的化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952188A1 (en) * 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3319944A4 (en) * 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20190140438A (ko) * 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해
AU2019249849C1 (en) 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
CA3167166A1 (en) * 2020-01-10 2021-07-15 Amgen Inc. Smarca2-vhl degraders

Also Published As

Publication number Publication date
JP2026082834A (ja) 2026-05-19
WO2022029617A1 (en) 2022-02-10
MX2023001445A (es) 2023-05-08
EP4192835A1 (en) 2023-06-14
CA3188024A1 (en) 2022-02-10
BR112023002089A2 (pt) 2023-02-28
JP7857914B2 (ja) 2026-05-13
US20240018134A1 (en) 2024-01-18
AU2021320052A1 (en) 2023-03-23
US12570650B2 (en) 2026-03-10
CN116529250A (zh) 2023-08-01
EP4192835A4 (en) 2024-08-21
JP2023536504A (ja) 2023-08-25
US20260184705A1 (en) 2026-07-02
KR20230061349A (ko) 2023-05-08

Similar Documents

Publication Publication Date Title
US12570650B2 (en) 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders
US12371426B2 (en) Pyridazine derivatives as SMARCA2/4 degraders
EP4067344B1 (en) Cycloalkyl urea derivative
JP7762306B2 (ja) 選択的parp1阻害剤およびその用途
KR20210049895A (ko) 고 활성 sting 단백질 작용제 화합물
WO2014134776A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2015026683A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
US11352357B2 (en) Cycloalkylurea derivative
TW201617344A (zh) 新穎四氫吡啶并嘧啶化合物或其鹽
US20240398812A1 (en) Modulators of trpml, their compositions and methods of use
EP3707136A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
EP4695250A1 (en) Tetracyclic compounds as smarca2 and/or smarca4 degraders
EP3793996A1 (en) Kinase inhibitors
JP2024502106A (ja) c-MYC mRNA翻訳調節因子及び癌治療におけるそれの使用
EP2920154B1 (en) Novel imidazol-piperidinyl derivatives as modulators of kinase activity
EA052684B1 (ru) 6​-замещенные пиридазиновые соединения в качестве деструкторов smarca2 и/или smarca4
WO2023152666A1 (en) 3-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
AU2020360928A1 (en) Azepan derivative
WO2025094065A1 (en) Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
WO2025196686A1 (en) Fused bicyclic compounds as smarca2 and/or smarca4 degraders
KR20250170567A (ko) 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도
WO2026080493A1 (en) COMPOUNDS FOR THE TARGETED DEGRADATION OF PKA Cα
HK40074199A (en) Cycloalkyl urea derivative